Research ArticleArticle
Open Access
Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis
Edward C. Keystone, Désirée van der Heijde, Arthur Kavanaugh, Hartmut Kupper, Shufang Liu, Benoît Guérette and Neelufar Mozaffarian
The Journal of Rheumatology July 2013, jrheum.120964; DOI: https://doi.org/10.3899/jrheum.120964
Edward C. Keystone
From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; University of California San Diego, La Jolla, California, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; and AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc. sponsored the study (). Dr. Keystone has received consulting fees or other remuneration from, and served on advisory boards on behalf of, AbbVie, AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has speaker honoraria agreements with AbbVie, Amgen, BMS, Janssen, Merck, Pfizer, Roche and UCB. Dr. van der Heijde has received consulting fees or other remuneration from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth, and is the director of Imaging Rheumatology bv. Dr. Kavanaugh has received consulting fees or other remuneration and research grants from AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. Drs. Kupper, Liu, Guérette, and Mozaffarian are employees of AbbVie Inc. and may hold stock or stock options. E.C. Keystone, MD, University of Toronto; D. van der Heijde, MD, PhD, Leiden University Medical Center; A. Kavanaugh, MD, University of California San Diego; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; S. Liu, PhD; B. Guérette, PhD; N. Mozaffarian, MD, PhD, AbbVie Inc. Address correspondence to Dr. E.C. Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, ON M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication May 9, 2013.
Désirée van der Heijde
From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; University of California San Diego, La Jolla, California, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; and AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc. sponsored the study (). Dr. Keystone has received consulting fees or other remuneration from, and served on advisory boards on behalf of, AbbVie, AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has speaker honoraria agreements with AbbVie, Amgen, BMS, Janssen, Merck, Pfizer, Roche and UCB. Dr. van der Heijde has received consulting fees or other remuneration from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth, and is the director of Imaging Rheumatology bv. Dr. Kavanaugh has received consulting fees or other remuneration and research grants from AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. Drs. Kupper, Liu, Guérette, and Mozaffarian are employees of AbbVie Inc. and may hold stock or stock options. E.C. Keystone, MD, University of Toronto; D. van der Heijde, MD, PhD, Leiden University Medical Center; A. Kavanaugh, MD, University of California San Diego; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; S. Liu, PhD; B. Guérette, PhD; N. Mozaffarian, MD, PhD, AbbVie Inc. Address correspondence to Dr. E.C. Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, ON M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication May 9, 2013.
Arthur Kavanaugh
From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; University of California San Diego, La Jolla, California, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; and AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc. sponsored the study (). Dr. Keystone has received consulting fees or other remuneration from, and served on advisory boards on behalf of, AbbVie, AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has speaker honoraria agreements with AbbVie, Amgen, BMS, Janssen, Merck, Pfizer, Roche and UCB. Dr. van der Heijde has received consulting fees or other remuneration from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth, and is the director of Imaging Rheumatology bv. Dr. Kavanaugh has received consulting fees or other remuneration and research grants from AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. Drs. Kupper, Liu, Guérette, and Mozaffarian are employees of AbbVie Inc. and may hold stock or stock options. E.C. Keystone, MD, University of Toronto; D. van der Heijde, MD, PhD, Leiden University Medical Center; A. Kavanaugh, MD, University of California San Diego; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; S. Liu, PhD; B. Guérette, PhD; N. Mozaffarian, MD, PhD, AbbVie Inc. Address correspondence to Dr. E.C. Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, ON M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication May 9, 2013.
Hartmut Kupper
From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; University of California San Diego, La Jolla, California, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; and AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc. sponsored the study (). Dr. Keystone has received consulting fees or other remuneration from, and served on advisory boards on behalf of, AbbVie, AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has speaker honoraria agreements with AbbVie, Amgen, BMS, Janssen, Merck, Pfizer, Roche and UCB. Dr. van der Heijde has received consulting fees or other remuneration from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth, and is the director of Imaging Rheumatology bv. Dr. Kavanaugh has received consulting fees or other remuneration and research grants from AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. Drs. Kupper, Liu, Guérette, and Mozaffarian are employees of AbbVie Inc. and may hold stock or stock options. E.C. Keystone, MD, University of Toronto; D. van der Heijde, MD, PhD, Leiden University Medical Center; A. Kavanaugh, MD, University of California San Diego; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; S. Liu, PhD; B. Guérette, PhD; N. Mozaffarian, MD, PhD, AbbVie Inc. Address correspondence to Dr. E.C. Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, ON M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication May 9, 2013.
Shufang Liu
From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; University of California San Diego, La Jolla, California, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; and AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc. sponsored the study (). Dr. Keystone has received consulting fees or other remuneration from, and served on advisory boards on behalf of, AbbVie, AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has speaker honoraria agreements with AbbVie, Amgen, BMS, Janssen, Merck, Pfizer, Roche and UCB. Dr. van der Heijde has received consulting fees or other remuneration from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth, and is the director of Imaging Rheumatology bv. Dr. Kavanaugh has received consulting fees or other remuneration and research grants from AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. Drs. Kupper, Liu, Guérette, and Mozaffarian are employees of AbbVie Inc. and may hold stock or stock options. E.C. Keystone, MD, University of Toronto; D. van der Heijde, MD, PhD, Leiden University Medical Center; A. Kavanaugh, MD, University of California San Diego; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; S. Liu, PhD; B. Guérette, PhD; N. Mozaffarian, MD, PhD, AbbVie Inc. Address correspondence to Dr. E.C. Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, ON M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication May 9, 2013.
Benoît Guérette
From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; University of California San Diego, La Jolla, California, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; and AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc. sponsored the study (). Dr. Keystone has received consulting fees or other remuneration from, and served on advisory boards on behalf of, AbbVie, AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has speaker honoraria agreements with AbbVie, Amgen, BMS, Janssen, Merck, Pfizer, Roche and UCB. Dr. van der Heijde has received consulting fees or other remuneration from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth, and is the director of Imaging Rheumatology bv. Dr. Kavanaugh has received consulting fees or other remuneration and research grants from AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. Drs. Kupper, Liu, Guérette, and Mozaffarian are employees of AbbVie Inc. and may hold stock or stock options. E.C. Keystone, MD, University of Toronto; D. van der Heijde, MD, PhD, Leiden University Medical Center; A. Kavanaugh, MD, University of California San Diego; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; S. Liu, PhD; B. Guérette, PhD; N. Mozaffarian, MD, PhD, AbbVie Inc. Address correspondence to Dr. E.C. Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, ON M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication May 9, 2013.
Neelufar Mozaffarian
From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; University of California San Diego, La Jolla, California, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; and AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc. sponsored the study (). Dr. Keystone has received consulting fees or other remuneration from, and served on advisory boards on behalf of, AbbVie, AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has speaker honoraria agreements with AbbVie, Amgen, BMS, Janssen, Merck, Pfizer, Roche and UCB. Dr. van der Heijde has received consulting fees or other remuneration from AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth, and is the director of Imaging Rheumatology bv. Dr. Kavanaugh has received consulting fees or other remuneration and research grants from AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. Drs. Kupper, Liu, Guérette, and Mozaffarian are employees of AbbVie Inc. and may hold stock or stock options. E.C. Keystone, MD, University of Toronto; D. van der Heijde, MD, PhD, Leiden University Medical Center; A. Kavanaugh, MD, University of California San Diego; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; S. Liu, PhD; B. Guérette, PhD; N. Mozaffarian, MD, PhD, AbbVie Inc. Address correspondence to Dr. E.C. Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, ON M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication May 9, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis
Edward C. Keystone, Désirée van der Heijde, Arthur Kavanaugh, Hartmut Kupper, Shufang Liu, Benoît Guérette, Neelufar Mozaffarian
The Journal of Rheumatology Jul 2013, jrheum.120964; DOI: 10.3899/jrheum.120964
Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis
Edward C. Keystone, Désirée van der Heijde, Arthur Kavanaugh, Hartmut Kupper, Shufang Liu, Benoît Guérette, Neelufar Mozaffarian
The Journal of Rheumatology Jul 2013, jrheum.120964; DOI: 10.3899/jrheum.120964